biomed devic servic
price close busi june
thought ada look pois
upsid maintain buy pt
thought ada maintain buy rate lift estim come
ada ahead expect strong support underli
market strength across cgm earli contribut limit disrupt
competit entrant sum robust share perform ytd
stretch valuat multipl consensu revenu continu see
ampl opportun upsid bia estimates/guid
beyond support view technolog superior product pipelin
defens posit pediatr hypo-unawar patient medicar adopt
although libr approv make harder ou strength
enthusiasm continu grow ada clear recent approv
reson academ clinic commun point
attend multipl symposia present product fair cours
meet came away nearli unanim posit feedback regard clinic
util across patient popul initi feedback
gather libr launch increas attent system cost form factor
usabl new featur off-set nearli competit sell point
libr asid cost bring best class accuraci particularli hypo rang
well real-tim alerts/alarm clinician spoke reiter focu
accuraci reliabl key point prefer advis patient
technolog choic said clear sale market push abbott
brought signific attent cgm technolog expect boat rise
cgm space patient awar grow technolog adopt increas
estim go dilig ada suggest commerci momentum
continu market adopt cgm technolog
acceler competit entrant yet impact patient start attrit
price repres headwind guidanc point
adjust forward estim modestli expect better expect
new patient addit model revenu
consensu note estim still
contempl msd headwind us commerci hardwar sensor
attrit rate believ offer
addit upsid opportun
valuat increas price target updat forward
estim adjust increas broader group multipl well
modestli increas revenu assumpt base valuat ev/sal
multipl appli sale estim assum cash
debt share outstand
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
chang estim
come ada feel increment confid abil deliv
revenu top end guidanc rang support underli market
strength across cgm earli contribut limit disrupt
competit entrant accordingli made follow chang full-year
figur summari chang estim
buy unchang target price june
biomed devic servic
except ep newold newold product
util high-growth med-tech comp group trade mean ev/sal
multipl estim revenu sum increas price target
larg result higher comp group multipl price target
base ev/sal multipl appli revenu estim
price target assum cash debt share
outstand
figur matrix discount rate impli share price target
buy unchang target price june
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price june
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price june
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin june et
date time product june et
price target base ev/sal multipl appli revenu estim price target assum
cash debt share outstand
price target base ev/sal multipl appli sale estim discount back
risk achiev target price valuat
market opportun could smaller project cgm could remain nich product patient aggress manag
blood glucos level remain case market penetr diabet popul would substanti
given number player well size competitor would limit opportun within market regulatori
delay could impact futur revenu uncertainti regard regulatori requir fda could delay new product may
impact new product commerci
busi senseon invest significantli develop current cgm system abil busi gener
return highli depend senseon abil develop cgm product achiev clinic regulatori success approv
commerci product
reimburs major revenu gener payment third parti payor manag
patient diabet senseon need ensur adequ coverag reimburs third parti payor includ government
healthcar program medicar medicaid order success futur cgm sale limit unless peopl
diabet receiv third parti reimburs insur carrier
competit senseon compet competit space multipl compani significantli resourc
senseon addit risk competit compani may product technolog enhanc
obsolet render product less competit cgm space
financi senseon incur signific net oper loss sinc incept expect incur net oper loss
forseeabl futur addit expect incur signific expens relat build-out us base sale
buy unchang target price june
biomed devic servic
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
